Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Glycemic Outcomes with Closed-Loop Insulin Delivery
Authors' conclusion
We conclude that HCL therapy may mitigate against the negative glycemic effects of DKA at T1D diagnosis.
Study context
- Population
- Adolescents using hybrid-closed loop (HCL) from diagnosis of T1D in the CLOuD trial
- Participants
- 51 adolescents
- Comparison
- Diabetic ketoacidosis (DKA) vs no DKA at diagnosis, all using HCL from T1D onset
- DKAn = 17
- No DKAn = 34reference
Primary result
As reported in the abstract
TIR 3.9-10.0 mmol/L (70-180 mg/dL), TBR (<3.9 mmol/L, <70 mg/dL) and HbA1c · 6, 12 and 24 months
- Similar TIR, TBR and HbA1c with vs without DKA at diagnosis
Further findings
Insulin requirements · 6 months
- Higher with DKA at diagnosis; not statistically significant after adjusting for bodyweight
Residual C-peptide secretion
- Similar between groups
Original publication
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Glycemic Outcomes with Closed-Loop Insulin Delivery. Diabetes Technol Ther. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →